CorMedix's short interest rose, yet positive earnings and analyst ratings buoyed its stock near $9.85.

CorMedix Inc., a biopharmaceutical company, saw its short interest increase by 8.9% to 6.84 million shares in November. Despite this, recent earnings surpassed expectations, with the company reporting better-than-expected EPS and revenue. Analysts like Needham & Company LLC and Rodman & Renshaw have given positive ratings, with target prices up to $18.00. The stock, however, remained stable at $9.85, reflecting a complex investor sentiment.

December 04, 2024
3 Articles

Further Reading